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Objective: Mild cognitive impaired (MCI) is viewed as a transitional stage from normal to
dementia. The aim of this study is analyze the sleep disturbances in subjects diagnosed as
carries MCI.
Methods: A review of the literature was conducted in order to document sleeps problems in
the context of MCI.
Results: Among the studies that compares the prevalence of sleep disturbances between
subjects with MCI and those with normal cognition demonstrated that night time
behaviors are more common in MCI patients (18.3–45.5%) than in normal population
(10.9–23.3%).
Conclusions: Sleep disturbance is prevalent and predictive of cognitive decline in older
people and in those with neurodegenerative disorders. The sleep problems have to be
identiﬁed and treat to preserve the cognition and the MCI subjects with sleep disturbances
have to be follow more closely to identify the initial signs of dementia.
& 2015 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Mild cognitive impaired (MCI) is viewed as a transitional
stage from normal to dementia. Patients affected with this
condition have a higher turn-over rate to Alzheimer0s dis-
ease (AD) with the average rate of 10–15% annually over 5
year [1]. But which of these patients will evolve to AD?
Which of these we have to follow more closely? And in the
future, if disease-modifying drugs for AD became available,
which patients will be chosen to take these medicines?
Maybe the answer is in the comorbidities, particularly the
neuropsychiatric ones.ep. Production and Hosti
licenses/by-nc-nd/4.0/).
r
54, Perdizes, São Paulo-S
an Association of Sleep.The deﬁnition of this transitional stage was proposed by
some authors like the National Institute of Mental Health
that, in 1986, proposed the term age-associated memory
impairment (AAMI) that characterize memory changes in
ageing which were felt to be a manifestation of normal
cognition [2]. But the most used concept is the one proposed
by Petersen in 2004 [3]. The essential features of these criteria
for MCI include: (i) memory complaint usually corroborated
by an informant, (ii) objective memory impairment for age,
(iii) essentially preserved general cognitive function, (iv)
largely intact functional activities, (v) not demented. No
particular test or cutoff score is speciﬁed. Beyond theng by Elsevier B.V. This is an open access article under the CC BY-
P. Brasil. CEP 05010-040.
S l e e p S c i e n c e 8 ( 2 0 1 5 ) 3 6 – 4 1 37deﬁnition, the author has been proposed clinical subtypes of
MCI. The criteria described deﬁne the amnestic MCI subtype
(aMCI) which is used for subjects who have memory impair-
ment. If no memory impairment is present then the subject
has non amnestic MCI (naMCI). After that, subject is classiﬁed
in aMIC-single domain or naMCI-single domain if only a single
domain (in case of aMIC is memory) is impaired or aMCI-
multiple domain or naMCI-multiple domain if multiple
domains are impaired (in aMCI it must be included memory).
The most typical MCI patient is one who has memory impair-
ment beyond what is expected to be normal for age but is
relatively intact in other cognitive domains and this impair-
ment is no sufﬁcient severity to constitute dementia [3].
The speciﬁc transition between normal ageing and MCI
can be quite subtle and the distinction between MCI and very
early dementia can also be challenging. Thus, attempts for a
combination of measures, clinical features, neuropsychologi-
cal testing, biomarkers and neuroimaging may be the key to a
more accurate diagnosis. Among clinical features, the neu-
ropsychiatric symptoms have been extensively studied. The
prevalence of these symptoms in MCI patients is around 50%
while at subjects with normal cognition is approximately 25%
[4,5]. Between neuropsychiatric symptoms the most common
are apathy (11.7–68%), depression/dysphoria (20–56%), sleep-
ing problems (18.3–56%) and anxiety (14.1–54%) [4–7]. The
reported prevalence for subjects with normal cognition for
apathy (0–4.8%), depression (11–16%), sleeping problems
(10.9–23%) and anxiety (5.0–26.7%) is lower than for MCI
individuals [4,7]. Although these symptoms are common in
subjects with MCI it is uncertain if they can predict AD in this
population, as a biomarker. The studies that try to answer
this question found contradictory results for the relationship
affective symptoms and AD [8–13]. Anyway, in any elderly
patients with neuropsychiatric symptoms, we should not
overlook the possibility of underlying cognitive impairment.
Sleeping problems are common in dementia. These pro-
blems can led to a worsening memory because the consolida-
tion of memories are made during the sleep time. And the
alterations in the person’s brain with AD can led to altera-
tions in sleep architecture [11]. The evaluation of sleep in
those with supposed risk for dementia may be relevant and
could be a potential target for early intervention. The aim of
this study is analyze the sleep disturbances in subjects
diagnosed as carries MCI, as a review of the studies published
until this moment.2. Method
A review of the literature was conducted in order to docu-
ment sleeps problems in the context of MCI. An exhaustive
MEDLINE and PUBMED search was performed for the period
of 2002 and February 2013 for all article cross-referenced for
“sleep disturbances” and “mild cognitive impairment”. Addi-
tional search was conducted using the terms “neuropsychia-
tric symptoms”. Only articles written in English or Portuguese
were searched. A total of 8 studies were selected due to their
relevance, methodology and accessibility. Of these 8 studies,
7 articles are clinical trials and 1 is a review article. Some
studies were excluded because they analyzed theneuropsychiatric symptoms but not analyzed clearly the
sleep disturbances.3. Results
3.1. Study design and setting
Among the 7 clinical trials, 3 reported cross-sectional data
[4,5,7] and 4 used a longitudinal design [6,14–16]. In 2 of the
longitudinal studies [14,15] the subjects were analyzed for 2
weeks, in 1 of them [16] the subjects were analyzed for 1 week
and there is an article [6] that follow-up the subjects for 10
years. The subjects who participated were selected in mem-
ory or neurology clinics [6,14–16] or the authors used the data
collected in a population-based samples [4,5,7].
The majority of the studies used the Petersen criteria for
MCI [3]. Only 1 study [6] used Global Deterioration Scale [17]
and another one [5] used the Statistical Manual of Mental
Disorders, Fourth Edition (DSM-4) [18] and they classiﬁed as
MCI the subjects that had some cognition impairment but not
meeting DSM-4 for dementia. The cognition level was assess-
ment by a test battery which is different in one study to
another. All studies used the Mini Mental Scale Examination
[19].
To access the presence and severity of neuropsychiatric
symptoms the Neuropsychiatric Inventory (NPI) [20] was
used at the cross-sectional studies. The NPI has scripted
screening questions for each of 12 domains: sleep, depres-
sion, anxiety, delusion, agitation/aggression, euphoria,
apathy, disinhibition, irritability, aberrant motor behavior,
hallucination and eating. If a positive response was obtained
in any domain, then the standardized questions focusing on
that positive feature would be used to explore the details
of frequency (range 1–4) and severity (1,mild; 2,moderate;
3,severe).
Not all studies used questionnaires to access sleep dis-
turbances. Two studies used actigraphy and one of them used
polysomnographic to note not only the subjective complaints
but also the objectives ones.
3.2. Prevalence of sleep disturbances
Among the studies that investigated the prevalence of sleep
disturbances in a population, they found distinguishing
features between subjects with MCI, those with normal
cognition and AD patients. The study conducted by Muang-
paisan compares subjects with and without cognitive impair-
ment and demonstrated that night time behaviors are more
common in MCI patients (45.5%) than in normal population
(23.3%) [7]. Another study comparing the same both popula-
tion report a prevalence of nigh time behaviors around 18.3%
in individuals whit MCI and 10.9% in individuals whit normal
cognition [4]. The article that used the Cardiovascular Healthy
Study to compare individuals classiﬁed as having dementia,
as having MCI and did not meet criteria for MCI and dementia
found that 8.8% of MCI participates have sleep disturbance,
comparing with 19.9% from AD patients, (the prevalence in
normal population was not available). According to this
article, sleep problems are the most frequent clinically
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among patients whit dementia [5]. The other study that
analyses people with dementia and compared with people
with MCI found a prevalence of 37% of sleeping problem in
the ﬁrst group and 56% in the second group [6]. This conﬂict-
ing results maybe be partially explained by the difference in
scale used in the latter study.
The study that used the polysomnographic to compare
sleep and memory in healthy older adults and MCI older
adults demonstrated some alterations in sleep and in mem-
ory. In sleep, patients with aMCI spent fewer minutes in
slow-wave sleep (SWS) than in the control group, the amount
of SWS is smaller in a aMCI group than in the control group,
theta were reduced during rapid-eye-movement (REM) and
both delta and theta were reduced in non-REM sleep in aMCI
patients compared with control and, ﬁnally, fast spindles
counts were reduced in aMCI patients at F3 and F4 recordings
sites compared to controls. In memory, recall was better in
the control group than in the aMCI group: controls improve
their recall in the morning relative to that in the evening
whereas aMCI patients did not. Instead, recalling less in the
morning compared to the evening. The same occur whit
recognition [16]. In a study using another method to analyze
sleep, the wrist-worn activity sensor, the authors found that,
in aMCI group, recognition was better when time in bed was
longer and memory decreased when the difﬁculty in falling
asleep increased [15]. However, comparing aMCI patients and
controls the actigraphy parameters failed to reveal signiﬁcant
differences. Other study using actigraphy in subjects with
naMCI, prove that greater number of wake arousals during
the rest interval were signiﬁcantly associated with poorer
nonverbal learning even after controlling for age. The greater
duration of wake after sleep onset (WASO) were signiﬁcantly
related to poorer performance on tests of attention, response
inhibition and concept forming/problem solving [14]. This
article do not included control group.4. Discussion
Anciently, we believe that sleep was just a passive process in
which the body only rested. Nearly the 50’ decade, the sleep
began to be seeing as a part of the circadian rhythms. While
we sleep, several centers and organic systems that inhibit
and/or activate important functions are working to provide
and regulate the sleep–wake cycle, core body temperature
and hormone secretion. The most important endogenous
pacemaker that regulates the sleep–wake cycle (and other
circadian rhythms) is the hypothalamic suprachiasmatic
nucleus. This nucleus receives daylight stimuli from retina
and sends stimuli to the pineal which is responsible for
melatonin production. The melatonin exercises a syncroniza-
tion effect at circadian rhythms and can also promote sleep
[21]. With aging, the suprachiasmatic nucleus may deterio-
rate and light exposure may decrease, also decreasing the
melatonin production and leading to the disruption of circa-
dian rhythms. The aftermaths of this disruption is a change
in sleep in elderly and, more pronounced, in AD patients, in
which the alterations in cerebral structure are greater. The
most common changes are decrease in sleep time efﬁcient,greater sleep fragmentation, with more frequent and longer
periods of WASO, increase in naps, decreased levels of SWS
tendency to go sleep and wake up earlier [22].
The AD is associated with the multiple neurotransmitter
systems dysfunction including cholinergic, noradrenergic
and serotoninergic systems, which also are part of the
sleep–wake system [23]. The cholinergic system is involved
with a large number of behaviors that are changed in severe
AD as attention, learning and memory as well as in sleep–
wake cycle [24]. The cholinergic pathways from basal nucleus
to the cortex along with the cholinergic pathways from
brainstem to the thalamus are involved with the wake
promotion and maintenance, as part of the ascending reti-
cular activating system [25,26]. Thus, is probable that the
impairment at cholinergic pathways results in an improve in
daytime sleepiness already in the early stages of AD [27] and
maybe in the MCI subjects. In addition, there are some
studies that suggest the redistribution of memory to pre-
frontal cortex during sleep for memory consolidation [28,29].
Therefore, prefrontal dysfunction found in AD and aMCI may
also be relevant for consolidation [30,31].
Recently the sleep spindles that appear on stage 2 sleep
are also implicated in memory consolidation. It may possible
because the sleep-related memory consolidation is supposed
to occur though a dialogue between the hippocampus and
neocortical areas, in which sleep spindles appear to play an
important role [32]. An study performed with polysomnogra-
phy compared 14 healthy elderly subjects with 14 AD patients
and conclude that a more pronounced fast spindles decrease
became evident in AD patients compared to old controls [33].
In the population situated between normal ageing and
dementia, people with MCI, we expect to ﬁnd some altera-
tions. Several studies try to prove this theory. The studies
demonstrated that sleep disturbances are prevalent in MCI
patients, regardless of type of study (cross-sectional or long-
itudinal), the criteria for MCI (Petersen criteria or DSM-4) or
the tool used (inventory, actigraphy and polysomnographic).
In studies that quantiﬁed this prevalence, its range about
8.8% [5] until 45.5% [7]. Comparing to subjects without
cognitive impairment that have a prevalence between 10.9
[4] and 23.3% and to patients with AD that prevalence of sleep
problems, in the literature, can reach 54% [34]. The MCI
patients are in the middle, as we might expect in this
transitional state. The differences between prevalence maybe
is due to the differences in criteria used to MCI, the chosen
sample, the follow-up period and the type of study, if cross-
section or longitudinal. The second point is the relevance of
the sleep problems. At the previous analyze studies, sleep
problems appears as being 1 of the 4 most common neurop-
sychiatric symptoms and were often clinically signiﬁcant,
may result in the need for institutionalization. So it is
important to recognize the sleep problems in this population.
Despite the prevalence of sleep disturbs be set between
elderly individuals without cognitive impairment and
dementia patients, the progression of MCI subjects with sleep
problems to dementia is still undeﬁned. A longitudinal study
that accompanied MCI patients for 10 years conclude, as a
major ﬁnding, that sleeping problems were associated with
decrease risk for AD [6]. The authors report that this ﬁnding is
in contrast with the literature and justiﬁed the differences
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results can varies if is conducted in a community or in a
clinical setting, may depend on the type of rating scale used
and the variability may have resulted from an interaction
between age, MCI type, the length of the follow-up period,
setting, vascular risk factors and diagnostic instruments.
Another data also concluded that sleep disturbances alone
was not signiﬁcantly different between MCI patients who
remained stable and those who progressed to AD after 25
months on average [35]. On the other hand, two studies
demonstrated that the presence of sleep problems in healthy
older adults was associated with the incidence of cognitive
decline or dementia [36,37] and another ones identiﬁed the
relationship between this two condition, as we describe
hereafter.
To further investigate, some authors analyze the sleep,
using actigraphy or polysomnographic, to better understand-
ing what occurs during the MCI patients sleep. In normal
aging, there are some changes in the sleep structure as poor
sleep efﬁciency, fragmented sleep, increased in frequency of
daytime napping, propensity in fall asleep and wake up
earlier and decreased levels of SWS [38,39]. In AD patients,
there are the same alterations but in higher intensity [40].
MCI is classiﬁed as a transitional stage between normal aging
and dementia, then we expected that these patients present
the same alterations described in an intermediate intensity.
A study that submitted aMCI patients into polysomnographic
demonstrated that SWS is dramatically reduced in aMCI,
together with borderline changes in REM, REM latency,
WASO, sleep efﬁciency, lower delta and theta power during
sleep and reduced stage-2 spindle counts at frontal recording
sites [16]. The authors speculate that SWS begins to decline in
healthy aging and then declines further in aMCI and DA,
whereas in advanced stages of AD, REM decline accelerates
such that SWS. A study using an actigraphy in 15 MCI
patients also showed a fragmented sleep and poor sleep
efﬁciency, as described in the literature [14]. Despite this
results, when MCI patients were compared with healthy
elderly controls, a study also using actigraphy parameters,
failed to reveal signiﬁcant differences between the groups,
although they observed a trend for phase-delayed in aMCI
subjects [15]. This fact possibly occur because the small
number of participants (ten aMCI patients and ten controls).
These three studies described above that analyze the
presence of changes in the sleep patterns also analyze the
relationships between sleep and memory and reached inter-
esting results [14–16]. The data that used the polysomno-
graphic recruited 16 cognitively healthy older adults and 8
aMCI patients and submitted the both groups to 2 declarative
memory tests (word-pair recall, fact recognition) and 1 non-
declarative memory test (object priming) at night before the
register and repeated the tests in the morning after poly-
somnographic. After 1 week the subjects was submitted to
the same protocol. They found that controls improved their
recall in the morning relative to that in the evening whereas
aMCI patients did not. The same occur with recognition. They
conclude that these difﬁculties in memory processes during
sleep are due to the reduction in delta/theta power, which are
associated with many types of memory, especially declara-
tive memory that was assessed before sleep, consistent withthe speculation that poor sleep contributes to poor memory
in MCI [16]. At the actigraphy studies, the authors cannot
explore the delta/theta power but they observed that better
sleep predicted better memory and when difﬁcult in falling
asleep increased, memory decrease. Participants who exhib-
ited greater across-night sleep variability showed lower story-
recall during the neuropsychological battery [15]. In another
study, the authors recruited 15 older adults that meet criteria
for naMCI and submitted them to a neuropsychological test
battery followed by the use of an actigraphy for 14 nights. The
results of the battery tests and the actigraphy register were
related and converged to two important conclusion: greater
number of WASO were signiﬁcantly associated with poorer
nonverbal learning, as well as concept for formation/problem
solving and greater durations of WASO were signiﬁcantly
related to poorer performance on tests of attention, response
inhibition and concept formation/problem solving [14].
The studies that were described emphasize the presence
of a-MCI and DA. But when we talk about MCI and sleep
disorders, there is another group which must be cited. Rapid
eye movement (REM) sleep behavior disorder (RBD) is a form
of parasomnia characterized by the presence of abnormal
and often violent motor manifestations during REM sleep
[41]. This abnormal behavior result from disorder of the deep
nuclei and brainstem neurons involved in the integration of
the sleep–wake cycle and the locomotor system [21]. A lot of
researches found a link between RBD and synucleinopathies
such as Parkinson disease (PD), Lewy body dementia (LBD)
and multiple system atrophy [41,42] and are even considered
to be early marker for these diseases [43]. In the consensus
criteria for LBD, RBD are considered to be suggestive features
of the disease [44]. Besides, a study that analyzes the
presence of MCI in patients with PD and RBD show that
prevalence of MCI in PD with RBD is 73%. In patients with
idiopathic RBD the prevalence is 50%, and in PD patients
without RBD this proportion decrease to 11%, nearly the same
as control subjects (8%) [45]. With this results, they suggest
that the presence of RBD is a major risk factor for MCI. Among
the subtypes of MCI, the naMCI single domain and aMCI
multiple domain were most associated with PD patients with
RBD, both characterized by a predominant impairment of
executive functions and attention. When Petersen described
the MCI criteria, this etiology was already presumed [3].
The analyzed studies do not mention another important
issue: the obstructive sleep apnea (OSA). This condition can
leads to cognitive deﬁcits mainly in memory and executive
functions [46–48]. While OSA does not cause dementia, it
could be considered to cause MCI. The patients with OSA is a
vulnerable patient due to the entire “package” of daytime
somnolence, disordered sleep, subclinical (or clinical) cere-
brovascular and cardiovascular disease. So by the possibility
of mimics a neurodegenerative disorder and is potentially
reversible with treatment, this condition must be investi-
gated and treated in subjects with decline in cognitive
functions. Furthermore the e4 allele of apolipoprotein E
(APOE), which is a major risk factor for AD [49], has been
associated with OSA in adults especially in the setting of
cognitive problems [50]. OSA is itself detrimental for cogni-
tion, especially among those at greater risk for AD due to
their APOE e4 carrier status.
S l e e p S c i e n c e 8 ( 2 0 1 5 ) 3 6 – 4 140Finally, both patients with cognitive impairment may have
sleep problems, because of the pathway neurodegeneration
common to the two functions, as patients with sleep problems
may develop cognitive impairment, because the dysfunction
that sleep disturbance cause in memory consolidation.5. Conclusion
Summarizing, sleep disturbance is prevalent and can be
predictive of cognitive decline in older people and in those
with neurodegenerative disorders. The sleep problems have
to be identiﬁed and treat to preserve the cognition and the
MCI subjects with sleep disturbances have to be follow more
closely to identify the initial signs of dementia.
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